Published in Med Clin North Am on February 01, 2013
The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression. Neuroimage Clin (2015) 1.48
Physical activity, fitness, and gray matter volume. Neurobiol Aging (2014) 1.34
Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement (2014) 0.84
Individualized Gaussian process-based prediction and detection of local and global gray matter abnormalities in elderly subjects. Neuroimage (2014) 0.81
Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disorders. Front Aging Neurosci (2015) 0.80
A comprehensive assessment of resting state networks: bidirectional modification of functional integrity in cerebro-cerebellar networks in dementia. Front Neurosci (2014) 0.80
An MRI study of age-related changes in the dimensions related temporal lobe. Int J Clin Exp Med (2014) 0.79
Differential vulnerability of white matter structures to experimental infantile hydrocephalus detected by diffusion tensor imaging. Childs Nerv Syst (2014) 0.79
mNos2 deletion and human NOS2 replacement in Alzheimer disease models. J Neuropathol Exp Neurol (2014) 0.78
Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease. PLoS One (2015) 0.78
Changes in cerebral vascular reactivity and structure following prolonged exposure to high altitude in humans. Physiol Rep (2015) 0.77
Evaluating the Predictive Power of Multivariate Tensor-based Morphometry in Alzheimers Disease Progression via Convex Fused Sparse Group Lasso. Proc SPIE Int Soc Opt Eng (2014) 0.77
Excessive variability in systolic blood pressure that is self-measured at home exacerbates the progression of brain white matter lesions and cognitive impairment in the oldest old. Hypertens Res (2015) 0.77
Segmentation of human brain using structural MRI. MAGMA (2016) 0.77
Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnestic MCI. Neuroimage Clin (2017) 0.76
Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform (2016) 0.75
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis (2016) 0.75
Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics. J Korean Med Sci (2015) 0.75
Midlife exercise blood pressure, heart rate, and fitness relate to brain volume 2 decades later. Neurology (2016) 0.75
Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism. Pharmacol Res Perspect (2016) 0.75
Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms. Front Aging Neurosci (2017) 0.75
Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimers Dement (Amst) (2017) 0.75
Tissue segmentation: a crucial tool for quantitative MRI and visualization of anatomical structures. MAGMA (2016) 0.75
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimers Res Ther (2017) 0.75
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Long-term cognitive and behavioral therapies, combined with augmentative communication, are related to uncinate fasciculus integrity in autism. J Autism Dev Disord (2012) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
Physiologic autonomic arousal heralds motor manifestations of seizures in nocturnal frontal lobe epilepsy: implications for pathophysiology. Sleep Med (2012) 1.51
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. Neurobiol Aging (2010) 1.35
Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci (2004) 1.33
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage (2009) 1.29
Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry (2002) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis (2010) 1.27
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Regional network of magnetic resonance imaging gray matter volume in healthy aging. Neuroreport (2006) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Age-related networks of regional covariance in MRI gray matter: reproducible multivariate patterns in healthy aging. Neuroimage (2009) 1.23
Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol Psychiatry (2010) 1.22
Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study. Psychiatry Res (2011) 1.21
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain (2008) 1.20
Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am J Psychiatry (2003) 1.19
Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol (2011) 1.19
Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol (2011) 1.18
Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther (2009) 1.17
Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One (2012) 1.17
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One (2011) 1.16
Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data. PLoS One (2013) 1.15
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener (2010) 1.15
Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol (2009) 1.12
Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement (2012) 1.12
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov (2013) 1.12
Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol (2006) 1.10
Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. Neuroimage (2011) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol (2009) 1.09
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology (2013) 1.08
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord (2009) 1.08
Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging (2008) 1.07
Convergent Findings of Altered Functional and Structural Brain Connectivity in Individuals with High Functioning Autism: A Multimodal MRI Study. PLoS One (2013) 1.07
Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol (2006) 1.07
Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. Cereb Cortex (2006) 1.05
The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. Alzheimers Dement (2008) 1.05
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet (2006) 1.04
Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High Throughput Screen (2005) 1.04
Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One (2012) 1.04
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn (2010) 1.03
White matter microstructure in relation to education in aging and Alzheimer's disease. J Alzheimers Dis (2009) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol (2011) 1.02
Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study. J Alzheimers Dis (2011) 1.02
Immunotherapy for Alzheimer's disease. Lancet Neurol (2003) 1.01
Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology (2002) 1.01
Increased hypothalamic expression of prolactin in lactation: involvement in behavioural and neuroendocrine stress responses. Eur J Neurosci (2002) 1.00
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging (2006) 1.00
Cognitive intervention in Alzheimer disease. Nat Rev Neurol (2010) 0.99
Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol (2011) 0.99
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging (2012) 0.98
Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One (2012) 0.98
Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Hum Brain Mapp (2009) 0.97
Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain (2004) 0.96
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med (2011) 0.96
Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology (2002) 0.96